Bach Pharma Newsletter

June 2020

Corporate Newsletter

June 2020| Issue 6

GVT & COVID-19

First, all of us at Bach Pharma hope that all of our Shareholders, Advisors, and Directors are healthy and safe during the current COVID-19 crisis around the globe. We know that as a nation and globally we are only in the first phase of fighting this new, terrible virus.

Bach Pharma is excited and encouraged with our recent research in Russia in conjunction with Salvim LLC on the effects of Galavit/GVT and symptoms of COVID-19 in patients. As our shareholders know, GVT has been available in Russia under the name Galavit. With the COVID-19 pandemic spreading, patients in Russia were given Galavit to see the effects it has on the symptoms of the virus. Early research seems to show that Galavit/GVT can successfully prevent and reverse symptoms in COVID-19 patients.

Specifically, Galavit/GVT prevents and reverses the effects of the Cytokine Storm in the body. In fact, it normalizes the regenerative activity in the cells and reduces the focus of inflammation in the proliferative stage.

To see our overview, click here.

Memorial Day reinforces Gulf War Illness

Focus for Bach Pharma

Last week, those of us in the United States experienced the most surreal Memorial Day in recent history. With many still at home, businesses closed and the country struggling to return to "normal", the meaning and messages of Memorial Day were blurred for many.

At Bach Pharma, Memorial Day serves as a reminder of our primary focus: The ability of GVT to affect and cure the effects of Gulf War Illness. We not only continue our current efforts to raise $2.2m to progress our ongoing GWI research but this holiday reinforced why we are doing it. Our ultimate goal is to get FDA approval for GVT in order to restore a quality of life to our veterans. While we fully believe that GVT will also help millions suffering from other neurodegenerative diseases, GWI remains our primary focus.

Spotlight on:

Dr. Victoria R. Rundus MD

Meet Dr. Victoria Rundus who was elected to the Bach Pharma Board of Directors at the recent Annual Meetings.

Dr. Victoria Rundus is an active pediatric practitioner in the Vanderbilt Integrated Providers Midsouth, practicing mainly in the offices of Gallatin Children’s Clinic, Gallatin, Tennessee and Lafayette Children’s Clinic in Lafayette, Tennessee. She started with the Gallatin Children’s Clinic in 2003 and has greatly enjoyed her job providing care for children for the last 17 years. Married, with one daughter, Dr. Rundus is a proud soccer mom.

Born in Lincoln, Nebraska and raised in Lumberton, North Carolina, Dr. Rundus earned her BS in Biology at the University of Houston, Houston, Texas, magna cum laude in 1991. She then went on to earn her MD at The University of Texas Health Center, San Antonio, Texas in 1999. During medical training, Dr. Rundus received a number of honors including the Society for Pediatric Research Medical Student Fellowship Award, Honors in Pediatrics, Medicine, Ob/Gyn, Family Practice, and Psychiatry clerkships, and Medical School Admissions Committee Member. Dr. Rundus completed her residency in pediatrics at Vanderbilt University and served as Chief Resident in Pediatrics from 2002 – 2003.

During the years between undergraduate and medical school, Dr. Rundus worked as a Research Associate with the Department of Craniofacial Growth and Development, at the Dental Branch of The University of Texas Health Sciences Center in Houston, Texas. Dr. Rundus’ research work was included in numerous peer reviewed publications, such as the Histochemical Journal, as well as other Abstracts and Oral Presentations. This prior research background has led to Dr. Rundus’ increased understanding and appreciation of the capabilities of Bach Pharma’s drug platform.

Dr. Rundus is an Associate Clinical Professor of Pediatrics at Vanderbilt, a member of the American Academy of Pediatrics, Certified in Pediatrics, and holds a TN State Medical License, Active through 2021.

Visit BachPharma.Com

After the redesign and relaunch of the Bach Pharma last year, we are constantly updating and adding information.

To keep abreast of all the current research, advancements and news in Bach Pharma, be sure to visit, Bach Pharma.com

‌

Find Bach Pharma Online

Bach Pharma is online. Find, like, share and support us at the links below:

Bach Pharma Twitter: HERE

Bach Pharma Facebook: HERE

Bach Pharma LinkedIn: HERE

Please follow, like and share Bach Pharma online.

Recent Annual Meeting Notes

On March 28, 2020 Bach Pharma Inc. held its annual meetings virtually. While not our original intent, these virtual meetings allowed us to reach and connect with more Shareholders than ever before.

a) Shareholders unanimously voted to elect as Directors of the Corporation the full slate of nominations presented to the shareholders. The following nominations were made and seconded to serve until the next annual meeting of shareholders until their successors are duly elected and qualified:

1 . Steven L. Stroup, MD 6. Ryan M. Schruender

2. C. Norman Spencer, MD 7. Daniel Cato

3. Mark O. Henry 8. Valeri Melekhov

4. Barbara A. Stima 9. Victoria R. Rundus, MD

5. Richard L. Prass, MD, PhD

b) Directors unanimously voted to elect the following Officers of the Corporation ; nominations were duly made and seconded to serve a 1 year term until their successors are duly elected and qualified at the next Annual Meeting of the Board of Directors:

Steven L. Stroup, MD Chairman of the Board

Steven L. Stroup, MD Chief Medical Officer

Mark O. Henry Interim Chief Executive Officer

Mark O. Henry Treasurer

Barbara A. Stima Vice President, Administration

Barbara A. Stima Secretary

Daniel Cato Vice President, Regulatory Affairs

Valeri Melekhov Vice President, Development

c) Directors unanimously voted to set the Meeting Dates for Board of Directors and Annual Meeting of Shareholders; interim meetings may be called during the year as needed; one in-person meeting is required each year:

Board of Directors Meeting Saturday, August 8, 2020

Board of Directors Meeting Saturday, November 21, 2020

Annual Meeting of Shareholders Saturday, March 27, 2021

Board of Directors Meeting Saturday, March 27, 2021

COMMENTS :

Bach’s previously voted motion to search for a high energy CEO is still ongoing and considered essential.

The Board would like nominations by January 23, 2021 for the slate of Directors for next year’s Annual Shareholder Meeting.

Bach Pharma | BachPharma.com